Comparing the current results to its competitors, Hutchmed China Limited reported Revenue decrease in the 4 quarter 2025 year on year by -12.96 %, despite the revenue increase by the most of its competitors of 7.7 %, recorded in the same quarter.
Hutchmed china Limited Net Income in the 4 quarter 2025 grew year on year by 1099.19%, faster than the Hutchmed China Limited's competitors average income growth of 22.66 %
Hutchmed China Limited's Comment on Competition and Industry Peers
The company operates in a competitive environment for the development and commercialization of new drugs, especially in kinase inhibition for cancer and other diseases. Its competitors include major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies globally. These competitors may discover, develop, or commercialize drugs before or more successfully than the company.
March 20, 2025
The quest for innovative treatments in oncology is ever-evolving, and recent data presented by HUTCHMED during key oncology congresses showcases significant advancements in lung cancer therapies, particularly in tackling MET-amplified non-small cell lung cancer (NSCLC). This article interprets the findings from the European Lung Cancer Congress 2025 and recent developments regarding the acceptance of the New Drug Application (NDA) in China for the combination of savolitinib and TAGRISSO. Key Findings from the SAVANNAH Phase II TrialThe results released from the SAVANNAH Phase II trial indicate that the combination of savolitinib (also known as ORPATHYS) and TAGRISSO (osimertinib) yields high and durable res...
September 24, 2024
In a significant milestone for cancer therapeutics, HUTCHMED Limited has received approval from the Japanese regulatory authorities for its promising oncology treatment, FRUZAQLA (fruquintinib). This approval, which is a noteworthy advancement in the fight against metastatic colorectal cancer, is a product of rigorous research and development, particularly stemming from the outcomes of the global Phase III FRESCO-2 trial. The collaborative efforts with Takeda Pharmaceutical Company Limited have underscored the importance of multinational partnerships in the realm of healthcare innovation.The FRESCO-2 trial, which evaluated the efficacy and safety of fruquintinib in patients with previously treated metastatic...
July 4, 2024
FDA Grants Priority Review Status to HUTCHMED s Tazemetostat for Relapsed or Refractory Follicular Lymphoma HUTCHMED (China) Limited, an innovative biopharmaceutical company, has announced that its New Drug Application (NDA) for tazemetostat, designated for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), has been accepted for review by the China National Medical Products Administration (NMPA). Impressively, the regulatory body has also granted Priority Review status to this application, reflecting the enormous potential of tazemetostat to address unmet medical needs. This breakthrough underlines HUTCHMED s commitment to advancing the treatment landscape for patie...
June 21, 2024
HUTCHMED and Takeda Gain European Commission Nod for FRUZAQLA in Metastatic Colorectal Cancer Treatment
Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 TrialThe biopharmaceutical landscape took a significant leap forward as HUTCHMED, in collaboration with Takeda, announced the European Commission s approval for FRUZAQLA (fruquintinib). This endorsement, directed towards patients with previously treated metastatic colorectal cancer (mCRC), marks a pivotal moment in the ongoing battle against one of the world s most formidable oncology challenges. The Phase III FRESCO-2 Trial: A Benchmark for EfficacyThe European Commission...
June 3, 2024
The treatment landscape for cancer is continuously evolving, with new therapeutic approaches and advanced research paving the way for improved patient outcomes. In this article, we explore the significant findings from the recent Phase III FRUTIGA clinical trial, as published in Nature Medicine, and the updated subgroup efficacy and quality of life data presented at the ASCO 2024 conference. These findings highlight the potential of FRUTIGA as a breakthrough treatment option for patients with certain types of cancer.FRUTIGA and its Mechanism of Action:FRUTIGA, developed by HUTCHMED, is a novel targeted therapy designed to inhibit specific enzymes involved in cancer growth and progression. By targeting these ...
HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a leading biopharmaceutical company dedicated to the discovery and development of innovative oncology and immunology therapies, is poised to make a significant impact at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The event, scheduled to take place from May 31 to June 4, 2024, both in Chicago, IL and online, will showcase new and updated data stemming from several of HUTCHMED's pioneering cancer treatment compounds.
The ASCO Annual Meeting is a premier event that convenes the brightest minds in oncology to share therapeutic advancements and clinical research that have the potential to redefine patient care. HUTCHMED's presentations will include updates on various compounds that have shown promising efficacy and safety profiles in treating multiple cancer forms. These developments align with HUTCHMED's mission to address significant unmet medical needs and improve patient outcomes through cutting-edge science.
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for AML Patients in China'
In a series of strategic milestones, HUTCHMED has also initiated the RAPHAEL registrational Phase III clinical trial of HMPL-306 in China, targeting patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 and/or IDH2 mutations. The trial commenced on May 14, 2024, with the first patient receiving their initial dose on May 11, 2024. HMPL-306, a highly selective, orally available inhibitor of IDH1 and IDH2, represents a significant scientific breakthrough with the potential to transform treatment paradigms for patients suffering from this aggressive and often intractable form of leukemia.
The initiation of the RAPHAEL trial underscores HUTCHMED’s commitment to expediting the clinical development of novel therapeutic options for hematological malignancies, addressing critical and unmet medical needs within the oncology domain.
Savolitinib's sNDA Accepted in China for NSCLC Treatment'
Furthermore, HUTCHMED has achieved another notable advancement with its targeted therapy savolitinib, as the supplementary New Drug Application (sNDA) has been accepted in China for the treatment of treatment-naïve or previously treated patients with locally advanced or metastatic MET exon 14 skipping non-small cell lung cancer (NSCLC).
As underscored by an oral presentation at the European Lung Cancer Congress 2024, Phase IIIb data revealed a median progression-free survival (PFS) of 13.7 months and a median overall survival (OS) that has yet to be reached in treatment-naïve patients receiving savolitinib. These encouraging results reaffirm savolitinib's therapeutic potential and set it apart as a promising option for managing MET exon 14 skipping alterations in NSCLC, a genetic subset renowned for its poor prognosis and limited treatment options.
Conclusion'
HUTCHMED's accomplishments and forthcoming presentations signal a momentous leap forward in cancer research and treatment. With their innovative compounds and rigorous clinical trials, they continue to pave the way for groundbreaking therapies that may significantly enhance survival and quality of life for cancer patients globally. As ASCO 2024 approaches, the oncology community eagerly anticipates the detailed findings and future potential of HUTCHMED's novel treatments.
HUTCHMED's cutting-edge developments exemplify a relentless pursuit of scientific innovation and therapeutic excellence, hallmarks that fortify their leading position in the global oncology landscape.
May 24, 2024
Cutting-Edge Oncological Advances: HUTCHMED s Groundbreaking Presentations at ASCO 2024 and Significant Developments in AML and NSCLC Treatments HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a leading biopharmaceutical company dedicated to the discovery and development of innovative oncology and immunology therapies, is poised to make a significant impact at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The event, scheduled to take place from May 31 to June 4, 2024, both in Chicago, IL and online, will showcase new and updated data stemming f...
May 14, 2024
In recent announcements, HUTCHMED (China) Limited has showcased its dedication to advancing the treatment landscape for two challenging medical conditions: mutated isocitrate dehydrogenase (IDH) 1 or 2 relapsed/refractory acute myeloid leukemia (AML), and warm antibody autoimmune hemolytic anemia (wAIHA). With the initiation of the Phase III trial for HMPL-306 in AML patients and the registration stage of the Phase II/III trial for sovleplenib in wAIHA patients, HUTCHMED aims to address the unmet medical needs of these patient populations in China. Furthermore, the company has also secured an acceptance and Priority Review status for the New Drug Application (NDA) for sovleplenib as a treatment for primary i...
January 11, 2024
NDA Acceptance for Sovleplenib in China: A Promising Breakthrough in Primary Immune Thrombocytopenia TreatmentIn a significant development for the field of hematology, HUTCHMED, a global biopharmaceutical company specializing in oncology and immunology, announced the acceptance of its New Drug Application (NDA) for Sovleplenib in China. This NDA has also been granted Priority Review status, following the Breakthrough Therapy designation received from the Chinese regulatory authorities in January 2022. The announcement marks a notable milestone in the quest for effective treatments for Primary Immune Thrombocytopenia (ITP), a rare autoimmune disorder characterized by a low platelet count.Primary Immune Thromb...
: In a recent announcement, HUTCHMED (China) Limited, a leading biopharmaceutical company, has successfully completed the enrollment phase of its Phase II/III clinical trial for fruquintinib in combination with sintilimab. This innovative treatment is being tested as a second-line option for patients suffering from locally advanced or metastatic renal cell carcinoma (RCC) in China. Additionally, a recent report also highlights HUTCHMED s impressive revenue growth in the fourth quarter of 2022, particularly in comparison to its competitors. Facts: HUTCHMED has achieved a significant milestone by finalizing patient enrollment for its Phase II/III trial of fruquintinib in combination with sint...
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Oncolytics Biotech Inc operates as a biotechnology company engaged in the development and commercialization of oncolytic viruses as potential therapeutics for the treatment of various cancers. Its business model revolves around identifying and acquiring intellectual property rights, conducting preclinical and clinical studies, and collaborating with pharmaceutical and biotechnology companies for the development and commercialization of its products. The company aims to deliver innovative and targeted cancer therapies to improve patient outcomes globally.
Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.
Sources:
Hutchmed china Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Hutchmed china Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
